Document:

<PAGE>   1

                                                                   Exhibit 10.90

                                   AGREEMENT

         THIS AGREEMENT ("AGREEMENT"), dated as of this 5th day of May, 2000,
is by and among Vision Twenty-One, Inc., (a/k/a Vision 21, Inc.) a Florida
corporation and Vision 21 of Southern Arizona, Inc., a Florida corporation
(collectively, "VISION 21"), Vital Sight, P.C., an Arizona professional
corporation (the "PRACTICE"), Ocusite-ASC, Inc., an Arizona corporation
("OCUSITE") and Jeffrey I. Katz, M.D., and Barry Kusman, M.D. (collectively,
the "SHAREHOLDERS").

                                R E C I T A L S

         WHEREAS, Vision 21 acquired the Non-medical Practice Assets (as
defined in Section 1(a) hereof) of Eye Institute of Southern Arizona, P.C.
pursuant to that certain Agreement and Plan of Reorganization dated as of
December 1, 1996 (the "ORIGINAL TRANSACTION AGREEMENT") and acquired certain
rights to the Non-medical ASC Assets (as defined in Section 1(a) hereof);

         WHEREAS, in connection with the Original Transaction Agreement, Vision
21 entered into a business management relationship with the Practice pursuant
to a Business Management Agreement (the "BMA");

         WHEREAS, the Shareholders desire to repurchase the Non-medical
Practice Assets and the Non-medical ASC Assets upon the terms and conditions
set forth herein; and

         WHEREAS, in furtherance of Vision 21's plan to exit the physician
practice management business, Vision 21, the Practice and the Shareholders
desire to terminate the business management relationship between the Practice
and Vision 21, and, upon closing, enter into an agreement pursuant to which the
Shareholders will have access to Vision 21's eye laser center in the Practice's
geographic area, all upon the terms and conditions set forth herein.

         NOW THEREFORE, in consideration of the mutual covenants set forth
herein, and intending to be legally bound hereby, the parties hereto hereby
agree as follows:

         SECTION 1.        BASIC TRANSACTION.

         (a)      PURCHASE AND SALE OF ASSETS. Effective as of the Closing Date
(as defined in Section 1(f) hereof), Vision 21 agrees to sell, transfer, convey
and deliver to the Shareholders on the terms and subject to the conditions set
forth herein, and the Shareholders agree to purchase from Vision 21, the
non-medical practice assets set forth on SCHEDULE 1(A)-1 hereto (the
"NON-MEDICAL PRACTICE ASSETS"). Effective as of the Closing Date, Vision 21
agrees to sell, transfer, convey and deliver to the Shareholders on the terms
and subject to the conditions set forth herein, and the Shareholders agree to
purchase from Vision 21 the non-medical ambulatory surgical center assets (the
"NON-MEDICAL ASC ASSETS") set forth on Schedule 1(a)-2 hereto related to the
Practice's ambulatory surgical center line of business (the "ASC") (the
Non-Medical Practice Assets and the

                                       1
<PAGE>   2

Non-medical ASC Assets may be collectively referred to as the "ASSETS"). The
Assets shall be free and clear of any liens or encumbrances except as otherwise
set forth herein.

         (b)      ASSUMPTION OF LIABILITIES. Effective as of the Closing Date,
Vision 21 shall assign to the Practice and/or Ocusite, and the Practice and/or
Ocusite shall assume and become responsible for (i) the outstanding accounts
payable incurred by Vision 21 relating to services, supplies and equipment
provided by Vision 21 to the Practice or the ASC in accordance with the BMA
prior to the Closing Date, (ii) each of the real property leases entered into
by Vision 21 for the office premises used by the Practice or the ASC, (iii)
each lease for equipment currently utilized in the office premises of the
Practice and/or the ASC specifically listed on the assumption agreement to be
executed and delivered at Closing in accordance with Section 1(i) hereof,
except for certain equipment leased by Principal Management Corporation ("PMC")
to Vision 21 which will be subleased by Vision 21 to the Practice pursuant to a
separate sublease agreement and Vision 21 shall be responsible for any claims
or liabilities arising out of the PMC equipment lease, (iv) each contract or
other obligation entered into by Vision 21 or the Practice for services or
equipment used in connection with the Practice and/or the ASC specifically
listed on the assumption agreement to be executed and delivered at Closing in
accordance with Section 1(i) hereof, (v) all obligations with respect to the
Employees (as defined in Section 1(g) hereof) for (1) paid time off ("PTO")
accrued prior to the Employee Termination Date (as defined in Section 1(g)
hereof); (2) payroll and any required withholding related thereto for the pay
period December 18, 1999 to December 31, 1999, and (3) all obligations with
respect to the Employees arising from and after the Employee Termination Date,
and (vi) all other obligations and liabilities relating to the Practice and/or
the ASC arising from and after the Closing Date. The Practice and the
Shareholders on the one hand and Vision 21 on the other hand, shall provide all
information to the other party necessary to set forth with specificity the
assumed liabilities on a schedule to the assumption agreement(s) to be
delivered at Closing in accordance with Section 1(i) hereof. The Practice and
the Shareholders shall use their best efforts to cause the landlord for each
real property location and each lessor of equipment to release Vision 21 from
any further obligations or liabilities under the real property or personal
property leases, which best efforts shall include, without limitation, the
personal guarantees of the Shareholders if requested by the landlords or the
lessors. At Closing, the Practice shall reimburse Vision 21 in an amount equal
to the aggregate of any security deposits paid by Vision 21 to the real
property or equipment lessors and not returned to Vision 21 at the time of the
Practice's and/or Ocusite's assumption of the lease obligations.

         (c)      BUSINESS MANAGEMENT AGREEMENT. Effective as of the Closing
Date, the BMA shall be terminated and of no further force or effect, and
neither Vision 21 nor the Practice or the Shareholders shall have any further
obligations or liabilities thereunder, except for those indemnification
obligations on the part of the Practice and the Shareholders regarding
malpractice claims which shall survive termination of the BMA, and except as
otherwise provided herein.

         (d)      CONSIDERATION. The aggregate amount of the consideration to
be given to Vision 21 in connection with the purchase of the Assets (the
"CONSIDERATION") shall be as follows:

                  (i)      Three Hundred Fifty Thousand and 00/100 ($350,000)
                  Dollars will be paid by the Shareholders at Closing by wire
                  transfer to Vision 21 of immediately available funds to an
                  account designated by Vision 21; and

                                       2
<PAGE>   3

                  (ii)     Effective as of the Closing Date, the Practice
                  and/or the Shareholders will transfer to Vision 21 One
                  Hundred Fifty Eight Thousand Six Hundred Seventy Seven
                  (158,677) shares of Vision 21 common stock and will authorize
                  Shumaker, Loop & Kendrick to release to Vision 21 for
                  cancellation the One Hundred Thirty Two Thousand One Hundred
                  Fifty Five (132,155) shares of Vision 21 common stock
                  currently held by it as Escrow Agent (collectively, the
                  "SHARES"), free and clear of any liens, claims, charges,
                  restrictions or encumbrances of any kind.

         (e)      INTENTIONALLY OMITTED.

         (f)      CLOSING DATE. The transactions contemplated by this Agreement
shall close (the "CLOSING") when this Agreement and all closing deliveries set
forth in Section 1(i) hereof are fully executed and/or delivered by the
parties. The effective date of Closing shall be January 1, 2000 (the "CLOSING
DATE").

         (g)      EMPLOYEES. The parties acknowledge and confirm that effective
December 18, 1999 (the "EMPLOYEE TERMINATION DATE") each of the employees of
Vision 21 set forth on SCHEDULE 1(G) hereto which Vision 21 employed to provide
services for the Practice or the ASC (the "EMPLOYEES") were terminated as
employees of Vision 21 and were hired as employees of the Practice. From and
after the Employee Termination Date, each of such Employees have been employees
of the Practice and the Practice shall continue to be responsible for paying
salaries, providing fringe benefits and for withholding, as required by law,
any sums for income tax, unemployment insurance, social security, or other
withholding required by applicable law or governmental requirement accruing
from and after the Employee Termination Date. The Practice shall maintain
appropriate workers' compensation coverage for all personnel employed by the
Practice and professional and comprehensive general liability insurance
covering the Practice and all of its personnel effective as of the Employee
Termination Date. Vision 21 shall remain liable for fringe benefits, other than
PTO, that accrued prior to the Employee Termination Date and for any salaries
and required withholdings from the date of the BMA to the Employee Termination
Date. On or prior to the Closing, Vision 21 shall satisfy any salary or fringe
benefit obligations, other than PTO, accrued prior to the Employee Termination
Date and the Practice shall obtain from each of the Employees a release
(collectively, the "Employee Releases") of Vision 21 from all of such
liabilities and from any and all other claims or liabilities of any kind or
nature related to Vision 21's employment of Employee.

         (h)      TERMINATION OF NONCOMPETITION COVENANT. Upon Closing, all
non-competition covenants between and among the parties set forth in the BMA,
Original Transaction Agreement and any related agreements shall be terminated
and of no further force or effect.

         (i)      DELIVERIES AT CLOSING.

                  (1)      At the Closing, Vision 21 shall deliver the
                           following documents:

                           (a)      Assignment(s) and Bill(s) of Sale with a
                           representation and warranty as to title and
                           ownership;

                                       3
<PAGE>   4

                           (b)      Duly executed assignments of leases for
                           each of the Practice's Offices and for the
                           Practice's and/or the ASC's leased equipment and the
                           equipment sublease agreement contemplated by Section
                           1(b) hereof for the equipment leased by PMC in form
                           acceptable to Vision 21 and the Practice;

                           (c)      Such other instruments of sale, transfer,
                           conveyance and assignment as the Practice or Ocusite
                           may reasonably request; and

                           (d)      Such other documents as may be necessary to
                           effectuate the transactions contemplated hereby; and

                           (e)      The Facility Access Agreement contemplated
                           by Section 1(k) hereof in form acceptable to the
                           parties thereto.

                  (2)      At the Closing, the Practice, Ocusite and the
                           Shareholders shall deliver the following documents:

                           (a)      The cash portion of the Consideration;

                           (b)      Stock certificates for the Shares duly
                           endorsed to Vision 21 or accompanied bystock powers
                           duly executed in blank;

                           (c)      Assumption agreement(s) in form acceptable
                           to Vision 21;

                           (d)      Such other instruments of assumption as
                           Vision 21 may reasonably request;

                           (e)      Such other documents as may be necessary to
                           effectuate the transactions contemplated hereby;

                           (f)      The Employee Releases in form acceptable to
                           Vision 21;

                           (g)      The Expense Reimbursement contemplated by
                           Section 1(j) hereof.;

                           (h)      The equipment sublease agreement
                           contemplated by Section 1(b) hereof for the equipment
                           leased by PMC in form acceptable to Vision 21 and the
                           practice; and

                           (i)      The Facility Access Agreement contemplated
                           by Section 1(k) hereof in form acceptable to the
                           parties thereto.

         (j)      EXPENSE REIMBURSEMENT. At the Closing, the Practice shall
reimburse Vision 21 for all Office Expenses, Practice Expenses and Shareholder
Expenses drawn on the Account, incurred subsequent to September 30, 1999 not
previously reimbursed by the Practice (the "EXPENSE REIMBURSEMENT"). In
addition to the payment at Closing by the Practice to Vision 21 of the
Consideration in accordance with Section 1(d) hereof, the Expense Reimbursement
shall be paid in cash by the Practice to Vision 21 at the Closing. Vision 21
shall provide the Practice with an accounting of the Expense Reimbursement at
least three (3) days prior to the Closing.

         (k)      FUTURE RELATIONSHIP. Effective as of the Closing Date, the
Shareholders will enter into a three (3) year facility access agreement (the
"FACILITY ACCESS AGREEMENT") with Vision 21 pursuant to which the Shareholders
shall have access to Vision 21's eye laser center in the Practice's geographic
area, which laser center is known as Arizona Eye Laser Center - Tucson (the
"LASER CENTER"). The Shareholders shall pay to Vision 21 a flat fee per laser
procedure performed by the

                                       4
<PAGE>   5

Shareholders at the Laser Center in accordance with the fee schedule set forth
in the Facility Access Agreement.

SECTION 2.        REPRESENTATIONS AND WARRANTIES.

         (a)      REPRESENTATIONS AND WARRANTIES OF VISION 21. Vision 21 hereby
represents and warrants to the Practice, Ocusite and the Shareholders that the
following are true and correct as of the date hereof and shall be true and
correct through the Closing as if made on that date:

                  (i)      Vision 21 is duly authorized to execute, deliver and
perform this Agreement and any other agreement contemplated hereby, and to
consummate the transactions contemplated hereby, and the Agreement and each
other agreement contemplated hereby are the legal, valid and binding
obligations of Vision 21, enforceable again.

                  (ii)     The information provided by Vision 21 with respect
to the assumed liabilities to be set forth in the assumption agreement to be
delivered at Closing will be true and correct in all respects.

                  (iii)    There are no third party approvals necessary on the
part of Vision 21 to consummate the transactions set forth herein, other than
(A) the approval of Vision 21's Board of Directors, the Audit Committee of
Vision 21's Board of Directors and the approval of the banks which are a party
to Vision 21's Credit Agreement (the "Banks"), which approvals have been
obtained prior to Vision 21's execution of this Agreement, and (B) the consents
required to be obtained in connection with the real and personal property
leases entered into by Vision 21 in connection with Practice, which consents
Vision 21 shall use its best efforts to obtain prior to Closing.

                  (iv)     There is no litigation pending or threatened which
would prevent the performance of Vision 21's obligations under this Agreement,
there is no bankruptcy proceeding pending or threatened to which Vision 21 is
subject, Vision 21 has not been adjudicated insolvent and consummation of the
transactions contemplated herein will not cause Vision 21 to become insolvent.

         (b)      REPRESENTATIONS AND WARRANTIES OF THE PRACTICE, OCUSITE AND
THE SHAREHOLDERS. The Practice and the Shareholders jointly and severally
hereby represent and warrant to Vision 21, and Ocusite represents and warrants
to Vision 21 as to those matters relating to it set forth in subsection (i),
(v) and (vi) below, that the following are true and correct as of the date
hereof and shall be true and correct through the Closing as if made on that
date:

                  (i)      Each of the Practice and Ocusite is duly authorized
                  to execute, deliver and perform this Agreement and any other
                  agreement contemplated hereby, and to consummate the
                  transactions contemplated hereby, and the Agreement and each
                  other agreement contemplated hereby are the legal, valid and
                  binding obligations of the Practice, Ocusite and the
                  Shareholders, enforceable against each such party in
                  accordance with their respective terms.

                  (ii)     Except as set forth on SCHEDULE 2(A)(II) hereto,
                  there are no prepaid expenses, unbilled accounts receivable,
                  unbilled services or similar items, and all ledger entries
                  and other

                                       5
<PAGE>   6

                  information provided by or on behalf of the Practice to
                  Vision 21 with respect to any revenue collected by or on
                  behalf of the Practice since the effective date of the BMA,
                  including receipts for Professional Eye Care Services and
                  ambulatory surgical procedures, have been complete and
                  accurate in all respects.

                  (iii)    Except as set forth on SCHEDULE 2(A)(III) hereto,
                  neither the Practice nor the Shareholders have incurred any
                  commitments, obligations or liabilities on behalf of or in
                  the name of the Practice since the effective date of the BMA.

                  (iv)     The information provided by the Shareholders and the
                  Practice with respect to the assumed liabilities to be set
                  forth in the assumption agreement to be delivered at Closing
                  will be true and correct in all respects.

                  (v)      There are no third party approvals necessary on the
                  part of the Practice, Ocusite or the Shareholders to
                  consummate the transactions set forth herein, other than the
                  approval of the Board of Directors of the Practice and
                  Ocusite, which approvals have been obtained prior to the date
                  of this Agreement.

                  (vi)     There is no litigation pending or threatened which
                  would prevent the performance of the Practice's, Ocusite's or
                  the Shareholders' obligations under this Agreement, there is
                  no bankruptcy proceeding pending against the Practice or
                  Ocusite, neither the Practice nor Ocusite has been
                  adjudicated insolvent and consummation of the transactions
                  contemplated herein will not cause the Practice or Ocusite to
                  become insolvent.

                  The Practice, Ocusite and the Shareholders acknowledge that
the approval of the transactions contemplated herein by Vision 21's Board of
Directors, the Audit Committee of Vision 21's Board of Directors and the Banks
is in reliance upon the representations and warranties of the Practice and the
Shareholders set forth herein.

         SECTION 3.        CONFIDENTIALITY AND NONDISPARAGEMENT COVENANTS.

         (a)      CONFIDENTIALITY COVENANT. Neither the Shareholders, Ocusite
nor the Practice shall, directly or indirectly, use for any purpose, or
disclose to any third party, any information of Vision 21 (whether written or
oral), including any business management or economic studies, patient lists,
proprietary forms, proprietary business or management methods, marketing data,
fee schedules, or trade secrets of Vision 21, and including the terms and
provisions of this Agreement and any transaction or document executed by the
parties pursuant to this Agreement. Notwithstanding the foregoing, the
Shareholders, Ocusite or the Practice may disclose any information that (a) is
or becomes generally available to and known by the public or the ophthalmic,
optometric or optical community (other than as a result of an unpermitted
disclosure directly or indirectly by the Shareholders or their affiliates,
advisors, or representatives); (b) is or becomes available to the Shareholders
on a nonconfidential basis from a source other than Vision 21 or its
affiliates, advisors or representatives, provided that such source is not and
was not bound by a confidentiality agreement with or other obligation of
secrecy to Vision 21 or its affiliates, advisors or representatives of which
the

                                       6
<PAGE>   7

Shareholders have knowledge; or (c) has already been or is hereafter
independently acquired or developed by the Shareholders without violating any
confidentiality agreement with or other obligation of secrecy to Vision 21 or
its affiliates, advisors or representatives. Without limiting the other
possible remedies to Vision 21 for the breach of this covenant, the
Shareholders, Ocusite and the Practice agree that injunctive or other equitable
relief shall be available to enforce this covenant, such relief to be without
the necessity of posting a bond, cash or otherwise.

         (b)      NONDISPARAGEMENT COVENANT. Vision 21, the Practice, Ocusite
and the Shareholders mutually agree that they shall not at any time make or
publish any disparaging comments or statements, whether written or oral, about
Vision 21, the Practice, Ocusite or the Shareholders, or their respective
officers, directors or employees.

         SECTION 4.        VISION 21 STOCK OPTIONS.

         (a)      SHAREHOLDER STOCK OPTIONS. Effective as of the Closing Date,
except for those Stock Option Agreements, if any, relating to a Shareholder's
services as a consultant, advisor or director for Vision 21, all Stock Option
Agreements, if any, between Vision 21 and any of the Shareholders shall be
deemed to be terminated except that any stock options which are fully vested as
of the Closing Date may be exercised (subject to forfeiture upon any breach by
the Shareholders of the restrictive covenants set forth in Section 5 and 15 of
this Agreement) within ninety (90) days after the Closing Date, in accordance
with the terms of the applicable Stock Option Agreement.

         (b)      STOCK OPTIONS OF EMPLOYEES AND PROFESSIONALS. Effective as of
the Employee Termination Date, all Stock Option Agreements, if any, between
Vision 21 and any Employees or any professional employees of the Practice shall
be deemed to be terminated except that any stock options which are fully vested
as of the Employee Termination Date may be exercised within ninety days after
the Employee Termination Date, in accordance with the terms of the applicable
Stock Option Agreement.

         SECTION 5.        INDEMNIFICATION.

         (a)      INDEMNIFICATION FOR BENEFIT OF VISION 21. The Practice,
Ocusite and the Shareholders, jointly and severally, shall defend, indemnify
and hold Vision 21 and its officers, directors, employees and agents harmless
and shall pay all losses, damages, fees, expenses or costs (including
reasonable attorney's fees) incurred by them based upon any claim arising out
of any breach by the Practice, Ocusite or the Shareholders of any of their
obligations, agreements, representations or warranties herein.

         (b)      INDEMNIFICATION FOR BENEFIT OF PRACTICE, OCUSITE AND
SHAREHOLDERS. Vision 21 shall defend, indemnify and hold the Shareholders, the
Practice, Ocusite and their officers, directors, employees and agents harmless
and shall pay all losses, damages, fees, expenses or costs (including
reasonable attorney's fees) incurred by them based upon any claim arising out
of any breach by Vision 21 of any of its obligations, agreements,
representations or warranties herein.

                                       7
<PAGE>   8

         SECTION 6.        MUTUAL RELEASES. Effective upon the Closing:

         (a)      The Shareholders, Ocusite and the Practice, and their
respective successors and assigns do hereby release and forever discharge
Vision 21 and its officers, directors, shareholders, partners, agents,
employees, affiliated entities, affiliated professionals, successors and
assigns, of and from any and all claims, demands, liabilities, costs, expenses,
actions and causes of action of whatsoever kind or nature, whether in law or
equity, from the beginning of time to the date of this Agreement, which the
Shareholders, Ocusite or the Practice may have or claim to have, whether known
to them or not, against Vision 21, except for the obligations under this
Agreement. This release is a general release and the parties intend and agree
that it shall be interpreted, construed and enforced as such.

         (b)      Vision 21 and its successors and assigns do hereby release
and forever discharge each of the Shareholders, Ocusite and the Practice, and
their respective officers, directors, shareholders, partners, agents,
employees, affiliated entities, affiliated professionals, successors and
assigns, of and from any and all claims, demands, liabilities, costs, expenses,
actions and causes of action of whatsoever kind or nature, whether in law or
equity, from the beginning of time to the date of this Agreement, which Vision
21 may have or claim to have, whether known to them or not, against the
Shareholders, Ocusite or the Practice, except for those indemnification
obligations on the part of the Practice, Ocusite and the Shareholders regarding
malpractice claims which shall survive termination of the BMA, and the
obligations under this Agreement. This release is a general release and the
parties intend and agree that it shall be interpreted, construed and enforced
as such.

         This Section 6 shall be of no force or effect until Closing.

         SECTION 7.        NO ASSIGNMENT OF CLAIMS; ADVICE OF COUNSEL. Each of
the parties warrants and represents that no part of any of the above asserted
or assertable claims have been assigned or transferred, and that it has full,
exclusive and unencumbered right, title and interest in and to them. Each of
the parties further warrants and represents that it has carefully read and
fully understands this Agreement (and the release provisions contained herein)
and has signed it voluntarily after being fully advised by its legal counsel.

         SECTION 8.        NO PRIOR BREACH. By executing this Agreement, the
parties hereto are not acknowledging a breach of any agreement between the
parties and affirm that the parties have mutually agreed not to continue the
previously established business relationships referred to herein, except as
otherwise provided herein.

         SECTION 9.        REMEDIES. The parties agree that a breach of this
Agreement by any party shall result in immediate and irreparable harm to the
other party hereto. Accordingly, the parties agree that the non-defaulting
parties may seek and obtain injunctive or other equitable relief as against the
defaulting party hereunder, without posting bond or other security, in addition
to any other remedies available at law or in equity.

         SECTION 10.       GOVERNING LAW. This Agreement shall be governed by
the laws of the state of Arizona without regard to such state's rules
concerning conflicts of laws. Any right to trial by jury with respect to any
claim or proceeding related to or arising out of this agreement is waived.

                                       8
<PAGE>   9

         SECTION 11.       ENTIRE AGREEMENT. This Agreement reflects the entire
agreement between the parties hereto with respect to the subject matter hereof
and no provision hereof may be modified or waived unless such modification or
waiver is in writing and is signed by both of the parties hereto.

         SECTION 12.       BINDING EFFECT. The provisions of this Agreement
shall be binding upon and inure to the benefit of the parties hereto.

         SECTION 13.       CONFIDENTIALITY. Except as and to the extent
required by law, including, without limitation any disclosures required under
federal and state securities and tax law, none of the parties hereto will, and
each will direct its officers, directors, employees, agents and representatives
not to, directly or indirectly, disclose or permit the disclosure of the terms
of this Agreement without the prior written permission of the other parties
hereto.

         SECTION 14.       ATTORNEYS' FEES. In the event of any litigation
arising out of or relating to this Agreement, the prevailing party shall be
entitled to recover all costs and reasonable attorneys' fees incurred,
including, but not limited to, costs and fees incurred in any investigations,
trials, bankruptcies and appeals.

         SECTION 15.       EXPENSES. Each of the parties shall be responsible
for and will pay its own expenses incurred in connection with the transactions
contemplated hereunder.

         SECTION 16.       DISCLAIMER OF WARRANTIES. THE ASSETS SHALL BE
TRANSFERRED TO THE PRACTICE AND OCUSITE "AS IS, WHERE IS" WITH NO WARRANTIES OR
REPRESENTATIONS OTHER THAN TITLE AND OWNERSHIP. VISION 21 DISCLAIMS ALL OTHER
WARRANTIES, EXPRESS OR IMPLIED, IN CONNECTION WITH THE ASSETS, INCLUDING BUT
NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTIBILITY AND FITNESS FOR A
PARTICULAR PURPOSE.

         SECTION 17.       FURTHER ASSURANCES. From and after the Closing Date,
upon the reasonable request of any party, the other party shall execute and
deliver such instruments, documents and other writings as may be reasonably
necessary to effectuate the intent and purpose of this Agreement.

         SECTION 18.       FULL ACCESS. After the Closing Date, the Practice
and the Shareholders shall provide Vision 21 with access, upon prior reasonable
written request specifying the need therefor, during regular business hours, to
the books of account and records of the Practice for the period from the date
of the Original Transaction Agreement until the Closing Date, and Vision 21 and
its representatives shall have the right to make copies of such books and
records.

         SECTION 19.       COOPERATION. Each of the parties hereto will
cooperate with the other in all respects, and each of the parties will execute
and deliver to the other parties hereto such other instruments and documents
and take such other actions as may be reasonably requested from time to time by
any other party hereto as necessary to carry out, evidence and confirm the
intended purposes of this Agreement. Such cooperation shall include, without
limitation, assistance to Vision 21 by the Shareholders and the Practice as
necessary in conjunction with the December 31,

                                       9
<PAGE>   10

1999 audit of Vision 21's financial statements, including the timely completion
of information requests or other inquiries as required by Vision 21 or Ernst &
Young. Cooperation by the Shareholders and the Practice with Vision 21's year
end audit shall be at no charge to Vision 21. The expense of Ernst & Young's
year end audit shall be borne by Vision 21.

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the date first above written.

VISION TWENTY-ONE, INC.                  VISION 21 OF SOUTHERN ARIZONA, INC.

By:  /s/ Bruce Maller                    By: /s/ Theodore N. Gillette
   ----------------------------------       ---------------------------------
         Bruce Maller, Chairman

VITAL SIGHT, P.C.                        OCUSITE-ASC, INC.

By: /s/ Barry Kusman                     By: /s/ Jeffrey I. Katz
   ----------------------------------       ---------------------------------
   Barry Kusman, M.D., its President        Jeffrey I. Katz, M.D., its President
   ------------------                       ---------------------

/s/ Jeffrey I. Katz
-------------------------------------
Jeffrey I. Katz, M.D. individually

/s/ Barry Kusman
---------------------------------------
Barry Kusman, M.D., individually

                                      10
<PAGE>   11

                                SCHEDULE 1(a)-1
                          NON-MEDICAL PRACTICE ASSETS

1)       Tangible assets consisting of all equipment, furniture, fixtures,
         inventory and leasehold improvements relating to the Practice to be
         more particularly described on the Assignment and Bill of Sale
         delivered at Closing.

2)       All trade names used by the Practice, other than Vision 21 or Vision
         Twenty-One, including, without limitation, the names "Eye Institute of
         Southern Arizona" or "Vital Sight".

3)       Cash in the Practice Operating Account, the BMA Account and the
         Practice petty cash fund as of the Closing Date.

4)       Any Accounts Receivable (net of allowance for contractual adjustments)
         assigned by the Practice to Vision 21 under the BMA which are
         outstanding as of the Closing Date.

                                      11
<PAGE>   12

                                SCHEDULE 1(a)-2
                             NON-MEDICAL ASC ASSETS

         The tangible assets consisting of all equipment, furniture, fixtures
and leasehold improvements relating to the ASC to be more particularly
described on the Assignment and Bill of Sale delivered at Closing.

                                      12
<PAGE>   13

                                 SCHEDULE 1 (g)

                               PRACTICE EMPLOYEES

See listing of Employees attached hereto.

                                      13
<PAGE>   14

                               SCHEDULE 2(a)(ii)

    Prepaid Expenses; Unbilled Accounts Receivable; Unbilled Services; etc.

None.

                                      14
<PAGE>   15

                               SCHEDULE 2(a)(iii)

                  Commitments; Obligations; Liabilities; etc.

None.

                                      15<PAGE>   1
                                                                    EXHIBIT 10.1

                                AUTONATION, INC.
                             1991 STOCK OPTION PLAN

                       (Effective as of October 29, 1991)
                 (As Amended and Restated as of April 17, 2000)

                  1. PURPOSE. The purpose of this 1991 Stock Option Plan
(hereinafter referred to as the "Plan") is to further the success of AutoNation,
Inc., a Delaware corporation (the "Company"), by replacing, as of the Effective
Date, the Republic Waste Industries, Inc. 1990 Stock Option and Stock Purchase
Plan (the "Prior Plan) and by making available Common Stock of the Company for
purchase by Participants (as defined below), and thus to provide an additional
incentive to such Participants to continue in the service of the Company or its
affiliates and to give them a greater interest as shareholders in the success of
the Company. Accordingly, the Committee is hereby authorized to designate those
Participants who are to receive Options under this Plan, and upon the due
execution of the Option Agreement, to grant options to such Participants.

                  2. DEFINITIONS. As used in this Plan, the terms set forth
below shall have the following meanings:

                  "BOARD" means the board of directors of the Company.

                  "CODE" means the Internal Revenue Code of 1986, as amended.

                  "COMMITTEE" shall have the meaning ascribed thereto in
Paragraph 3 hereof.

                  "COMMON STOCK" means the Company's common stock, par value
$0.01 per share.

                  "COMPANY" shall have the meaning ascribed thereto in Paragraph
1 hereof.

                  "DATE OF GRANT" means the date on which an Option is granted
hereunder.

                  "EFFECTIVE DATE" shall have the meaning ascribed thereto in
Paragraph 12 hereof.

                  "EXCHANGE ACT" means the Securities Exchange Act of 1934, as
amended.

                  "OPTION" means an Option granted pursuant to this Plan.

<PAGE>   2

                  "OPTION AGREEMENT" means a written agreement between the
Company and a Participant pursuant to which an Option or Options are granted to
a Participant under this Plan.

                  "OPTION PRICE" means the price per share of Common Stock,
determined under Paragraph 7(a) hereof, for which an Option may be exercised.

                  "OPTIONEE" shall mean the person who is entitled to exercise
an Option.

                  "PARENT" means a parent corporation of the Company as defined
in
Section 424(c) of the Code.

                  "PARTICIPANTS" means the employees and officers of the Company
or of any of its Subsidiaries or Parent and the directors serving on the Board.

                  "PLAN" shall have the meaning ascribed thereto in Paragraph 1
hereof.

                  "PRIOR PLAN" shall have the meaning ascribed thereto in
Paragraph 1 hereof.

                  "SUBSIDIARY" means a subsidiary corporation of the Company as
defined in Section 424(f) of the Code.

                  3. ADMINISTRATION OF PLAN. The Board of Directors of the
Company shall appoint a committee (the "Committee") composed of not less than
two persons to administer the Plan. Only directors who qualify as "outside
directors" under Rule 16b-3 promulgated under the Exchange Act shall be eligible
to serve as members of the Committee. The Committee shall report all action
taken by it to the Board, which shall review and, if thought appropriate, ratify
or approve those actions that are by law required to be so reviewed and ratified
or approved by the Board. The Committee shall have full and final authority in
its discretion, subject to the provisions of the Plan, to determine the
Participants to whom, and the time or times at which, Options shall be granted
and the number of shares and exercise price in respect of each Option; to
construe and interpret the Plan and any agreements made pursuant to the Plan; to
determine the terms and provisions (which need not be identical or consistent
with respect to each Participant) of the respective Option Agreements and
agreements ancillary thereto, including, without limitation, terms covering the
payment of the Option Price; and to make all other determinations and take all
other actions the Committee may think necessary or advisable for the proper
administration of this Plan. All such actions and determinations shall be
conclusively binding for all purposes and upon all persons.

                  4. OPTIONS AUTHORIZED. The Committee shall have the full power
and authority, in its sole discretion, to grant to an Optionee, in exchange for
the surrender and cancellation of an Option, a new Option having a purchase

                                       2
<PAGE>   3

price lower than that provided in the Option so surrendered and cancelled and
containing such other terms and conditions as the Committee may prescribe in
accordance with the provisions of this Plan.

                  5. COMMON STOCK SUBJECT TO OPTIONS. The aggregate number of
shares of Common Stock that may be issued upon the exercise of Options under the
Plan and stock options under the Prior Plan shall not exceed 5,000,000 shares,
subject to adjustment under the provisions of Paragraph 8; provided, however
that (a) the number of shares of Common Stock that may be issued upon the
exercise of Options on or after the Effective Date shall be the difference
between 5,000,000 and the total number of shares either issued, or subject to
issue upon the exercise of stock options granted, pursuant to the Prior Plan as
of the Effective Date; (b) the aggregate number of shares of Common Stock which
may be reserved for issuance under the Plan shall not exceed ten percent (10%)
of the number of shares of Common Stock issued and outstanding (on a non-diluted
basis) on such particular date; provided that no decrease in the number of
shares of Common Stock of the Company shall cause the number of shares of Common
Stock reserved for issuance the Plan to be less than that number required to be
issued upon the exercise of all outstanding and unexercised options issued
prior to such date; and (c) the number of shares of Common Stock reserved for
issuance at any one time to any one person shall not exceed five percent (5%) of
the Common Stock issued and outstanding (on a non-diluted basis). The shares of
Common Stock to be issued upon the exercise of Options may be authorized but
unissued shares or shares issued and reacquired by the Company. In the event and
to the extent any Option shall, for any reason, terminate expire or be
surrendered without having been exercised in full, the shares subject to such
Options shall again be available for Options to be granted under the Plan or be
used by the Company for any other purpose.

                  6. PARTICIPANTS. Except as herein otherwise provided, Options
may be granted under the Plan to any Participant. In determining the
Participants to whom Options shall be granted and the number of shares to be
covered by such Option, the Committee may take into account the nature of the
services rendered by the respective Participants, their present and potential
contributions to the Company's success, and such other factors as the Committee
in its discretion shall deem relevant. A Participant who has been granted an
Option under the Plan may be granted an additional Option or Options under the
Plan, in the Committee's discretion.

                  7. TERMS AND CONDITIONS OF OPTIONS. The grant of an Option
under the Plan shall be evidenced by an Option Agreement executed by the Company
and the applicable Participant and shall contain such terms and be in such form
as the Committee may from time to time approve, subject to the following
limitations and conditions:

                           (a) OPTION PRICE. The Option Price per share with
respect to each Option shall be determined by the Committee, but shall in no
instance be less than the greater of (i) the par value of the shares subject to
the Option and (ii) the fair market value of the shares subject to the Option as
of the Date of Grant. The Committee may permit the Option Price to be payable in
Common Stock owned by the holder of an Option. For purposes of this Paragraph

                                       3
<PAGE>   4

7(a), fair market value shall be, where applicable, the closing price of the
Common Stock on the most recent trading date immediately preceding the Date of
Grant as reported on the New York Stock Exchange composite tape or, if the
Common Stock is not traded on such exchange, as quoted on NASDAQ, or if the
Common Stock is not traded on such exchange or quoted on NASDAQ, then as
reported on any other securities exchange on which the Common Stock may be
traded.

                           (b) PERIOD OF OPTION. The expiration date of each
Option shall be fixed by the Committee, but, notwithstanding any provision of
the Plan to the contrary, such expiration date shall not be more than 9 years
from the Date of Grant.

                           (c) VESTING OF SHAREHOLDER RIGHTS. Neither an
Optionee nor his successor in interest shall have any of the rights of a
shareholder of the Company solely by virtue of the ownership of such Option
until the Option is exercised and the certificates relating to the shares for
which the Option is exercised are properly delivered to such Optionee or
successor.

                           (d) EXERCISE OF OPTION. Each Option shall be
exercisable from time to time over such period and upon such terms and
conditions as the Committee shall determine, but not at any time as to less than
25 shares unless the remaining shares that have become so purchasable are less
than 25 shares.

                           (e) NONTRANSFERABILITY OF OPTION. Options shall be
transferable only (i) by will or the laws of descent and distribution or (ii) as
otherwise expressly authorized by the Committee. Each Option shall be
exercisable during the Optionee's lifetime only by him or her or, during periods
of legal disability, by his or her legal representative or, to the extent the
Committee permits an assignment of an Option, by the assignee of the Optionee.
No Option shall be subject to execution, set-off, attachment or similar process,
other than by the Company. Following the Optionee's death, Options held by such
Optionee, to the extent exercisable, may be exercised by the executors or
administrators or legatees or distributees of such Optionee's estate.

                  8. ADJUSTMENTS. The Committee in its discretion, may make such
adjustments in the Option Price and the number of shares covered by outstanding
Options if such adjustments are required to prevent dilution or enlargement of
the rights of the holders of such Options that would otherwise result from any
reorganization. recapitalization, stock split, stock dividend, combination of
shares, merger, consolidation, issuance or rights, or other change in the
capital structure of the Company. The Committee, its discretion, also may make
such adjustments in the aggregate number of shares that may be subject to the
future grant of Options if such adjustments are appropriate to reflect any
transaction or event described in the preceding sentence.

                                       4
<PAGE>   5

                  9. RESTRICTIONS ON ISSUING SHARES. The exercise of each Option
shall be subject to the condition that if at any time the Company shall
determine in its discretion that the satisfaction of withholding tax or other
withholding liabilities, or that the listing, registration, or qualification of
any shares otherwise deliverable upon such exercise upon any securities exchange
or under any state or federal law, or that the consent or approval of any
regulatory body, is necessary, or desirable as a condition of or in connection
with, such exercise or the delivery or purchase of shares pursuant thereto, then
in any such event, such exercise shall not be effective unless such withholding,
listing, registration, qualification, consent or approval shall have been
effected or obtained free of any conditions not acceptable to the Company.

                  10. AMENDMENTS, SUSPENSION, AND TERMINATION OF PLAN. The Board
may at any time suspend or terminate the Plan or may amend it from time to time
in such respects as the Board may deem advisable in order that the Options
granted thereunder may conform to any changes in the law, or in any other
respect which the Board may deem to be in the best interest of the Company,
provided, however, that without approval by the shareholders of the Company
voting the proper percentage of its voting power, no such amendment shall make
any change in the Plan for which shareholder approval is required of the Company
by (a) Rule 16b-3, promulgated under the Exchange Act; (b) any rules for listed
companies promulgated by any stock exchange on which the Company's stock is
traded; or (c) any other applicable rule or law. Unless sooner terminated
hereunder, the Plan shall terminate 10 years after the Effective Date. No Option
may be granted during any suspension or after the termination of the Plan. No
amendment, suspension, or termination. of the Plan shall, without an Optionee's
consent, impair or negate any of the rights or obligations under any Option
theretofore granted to such Optionee under the Plan.

                  11. TAX WITHHOLDING. The Committee may, in its sole
discretion, (a) require an Optionee to remit to the Company a cash amount
sufficient to satisfy, in whole or in part, any federal. state, provincial and
local withholding tax requirements prior to the delivery of any certificate for
shares pursuant to the exercise of an Option hereunder; (b) grant to an Optionee
the right to satisfy, in whole or in part, any such withholding tax requirements
by electing to require that the Company, upon any exercise of the Option,
withhold from the shares of Common Stock issuable to the Optionee upon the
exercise of the Option, that number of full shares of Common Stock having a fair
market value equal to the amount or portion of the amount required to be
withheld or (c) satisfy such withholding requirements through another lawful
method, including through additional withholdings against the Optionee's other
wages with the Company.

                  12. EFFECTIVE DATE OF PLAN. This Plan shall become effective
on the date (the "Effective Date") on which it is adopted by the Board:
provided, however, the Plan shall be null and void and no Options granted under
the Plan shall be effective unless the Plan is approved within twelve (12)
months of its adoption by the Board by a majority (or such other proportion as
may be required by state law or the Articles of Incorporation of the Company) of

                                       5
<PAGE>   6

the outstanding voting shares of stock of the Company, voted either in person or
by proxy, at a duly held stockholders meeting. Any Optionee granted an Option
prior to such approval at a duly held stockholders meeting shall have no rights
to or interest in such Option until such approval has been given.

                  13. TERMINATION OF EMPLOYMENT. Except as otherwise provided in
Section 14 or as may otherwise be provided by the Committee, upon the
termination of employment or other service of an Optionee with the Company, a
Subsidiary, or a Parent for any reason, all Options held by such Optionee at the
time of such termination shall immediately terminate and such Optionee shall
have no further right to purchase shares of Common Stock pursuant to such
Option; provided, however, that, unless such termination is by the Company for
"Cause," all such Options, to the extent exercisable on the date of such
termination, shall remain exercisable until the earlier of (a) the expiration
date of such Option as fixed by the Committee pursuant to Section 7(b) and (b)
the first anniversary of the date of such termination. For purposes of the
foregoing, "Cause" shall mean (1) the Optionee's conviction for commission of a
felony or other crime; (2) the commission by the Optionee of any act against the
Company constituting willful misconduct, dishonesty, fraud, theft or
embezzlement; (3) the Optionee's failure, inability or refusal to perform any of
the material services, duties or responsibilities required of him by the
Company, or to materially comply with the policies or procedures established
from time to time by the Company, for any reason other than his illness or
physical or mental incapacity; (4) the Optionee's dependence, as determined in
good faith by the Company, on any addictive substance, including, but not
limited to, alcohol or any illegal or narcotic drugs; (5) the destruction of or
material damage to Company property caused by the Optionee's willful or grossly
negligent conduct; and (6) the willful engaging by the Optionee in any other
conduct which is demonstrably injurious to the Company or its subsidiaries,
monetarily or otherwise. Determination of Cause shall be made by the Committee
in its sole discretion. Notwithstanding the foregoing, if the Optionee is a
party to an employment agreement with the Company, "Cause" with respect to such
Optionee shall have the meaning set forth therein.

                  14. EXERCISE OF OPTION AFTER DEATH, DISABILITY OR RETIREMENT.
Except as otherwise provided by the Committee and notwithstanding anything in
Section 13 to the contrary, if an Optionee's termination of employment is by
reason of the death, "permanent and total disability" (within the meaning of
Section 22(e)(3) of the Code) or "Retirement"of such Optionee, all Options held
by such Optionee at the time of such termination shall become immediately vested
and exercisable in full and shall remain exercisable until the earlier of (a)
the expiration date of such Option as fixed by the Committee pursuant to Section
7(b) and (b) the 3rd anniversary of the date of such termination. Whether a
termination of employment or service is to be considered by reason of "permanent
and total disability" for purposes of this Plan shall be determined by the
Committee, which determination shall be final and conclusive. For purposes of
the foregoing, "Retirement" shall mean the Optionee's termination of employment
or other service from the Company or a Subsidiary after attainment of age 55 and

                                       6
<PAGE>   7

completion of at least 6 years of service with the Company or a Subsidiary. For
purposes of the preceding sentence, employment or other service with an entity
prior to its becoming a Subsidiary or after its ceasing to be a Subsidiary shall
be disregarded.

                  15. APPLICABLE PLAN. All Options granted by the Company
pursuant to the Prior Plan shall be governed by the terms and conditions of the
Prior Plan and shall be unaffected by the terms and conditions of this Plan.

                  16. CHANGE IN CONTROL. Should Michael G. DeGroote, MGD
Holdings Ltd. or any other entity, holding the common voting shares of the
Company on his behalf (collectively referred to as "MGD") lose control of the
Company, as decided by the Board in good faith, and if the Participant within
two (2) years of the date of that event be dismissed, otherwise than for cause,
death or disability, then all rights of the Participant to purchase shares under
the Plan, granted but unvested will vest immediately and the prescribed time
limits for exercise will run from such vesting. MGD will be deemed to have lost
control of the Company should MGD's effective holdings of the Company voting
shares drop below twenty percent (20%) of the outstanding voting shares.

                  17. DISTRIBUTION. Pursuant to that certain Employee Benefits
Agreement dated as of February 14, 1995 between the Company and Republic
Environmental Systems, Inc. ("RESI"), Options (hereinafter referred to as
"Affected Options") granted pursuant to the Plan on or before the record date
(the "Distribution Record Date"), as determined by the Board, for the
distribution by the Company to the Company's stockholders of all of its stock in
RESI (such distribution being hereinafter referred to as the "Distribution" and
the date of the Distribution being hereinafter referred to as the "Distribution
Date"), were adjusted, effective as of the. Distribution Date, such that (i) the
Option Price of each Affected Option or such portion thereof was adjusted by
multiplying said Option Price by a fraction, the numerator of which is the
Trading Price Per Share (as hereinafter defined) of the Common Stock and the
denominator of which is the sum of the Trading Price Per Share of the Common
Stock and 0.2 times the Trading Price Per Share of the common stock of RESI (for
this purpose, the "Trading Price Per Share" of the Common Stock or the common
stock of RESI, as the case may be, shall be the closing price of such security
as reported on the National Association of Securities Dealers Automated
Quotation Market on the Distribution Date), (ii) no Affected Option shall be
terminated pursuant to Paragraph 13 of the Plan for the reason that the Optionee
holding such Option is no longer an employee of the Company or of any Subsidiary
or Parent, provided that the Optionee remains an employee of RESI or any
subsidiary or parent of RESI and the Optionee shall be treated for all purposes
of said Paragraph 13 as if the Optionee instead had been employed by the Company
and (iii) an Affected Option shall continue to vest even though the Optionee
holding such Option is no longer an employee of the Company or of any Subsidiary
or Parent, provided that the Optionee remains an employee of RESI or of any
subsidiary or parent of RESI.

                                       7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}]]